Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Gene Editing of Pluripotent Stem Cell-Derived Hepatic Cells for Liver Disease Modeling and Therapeutic Development

  • Donghyun Lim (Department of Bioengineering, College of Engineering, and BK21 FOUR Education and Research Group for Biopharmaceutical Innovation Leader, Hanyang University) ;
  • Hyung-Ryong Kim (Department of Pharmacology, College of Dentistry, Jeonbuk National University)
  • Received : 2025.11.21
  • Accepted : 2025.12.10
  • Published : 2026.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

The growing demand for physiologically relevant human liver models has driven significant progress in generating hepatic cells and organoids derived from pluripotent stem cells. These regenerative cell sources serve as powerful platforms for elucidating the mechanisms underlying liver diseases and for evaluating drug responses under human-relevant conditions. Moreover, they hold tremendous promise as cell-based therapeutics for various hepatic disorders. The utility of these regenerative cell technologies is further expanded when combined with gene-editing techniques, which enable precise modeling of pathogenic variants and targeted correction of disease-associated mutations. Gene editing can also be leveraged to enhance the functionality and therapeutic potential of regenerative hepatocyte products. In this review, we summarize recent advances at the interface of gene editing and hepatic cell regeneration, emphasizing their applications in genetic disease modeling, therapeutic gene correction, drug testing, and cell-based therapies for liver disorders. We also provide an overview of major gene-editing tools and practical guidance for implementing them in pluripotent stem cells-based regenerative workflows, concluding with future perspectives on the integration of gene editing and regenerative hepatocyte technologies.

Keywords

Acknowledgement

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (grant number: RS-2023-00225239, RS-2023-00209725), by the Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korea government (grant number: KFRM24A0105L1), and by the research fund of Hanyang University (202500000001282).

References

  1. Abbey, D., Elwyn, S., Hand, N. J., Musunuru, K. and Rader, D. J. (2020) Self-organizing human induced pluripotent stem cell hepatocyte 3D organoids inform the biology of the Pleiotropic TRIB1 gene. Hepatol. Commun. 4, 1316-1331. https://doi.org/10.1002/hep4.1538
  2. Anzalone, A. V., Koblan, L. W. and Liu, D. R. (2020) Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824-844. https://doi.org/10.1038/s41587-020-0561-9
  3. Arruda, V. R. (2015) The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A. Haematologica 100, 849-850. https://doi.org/10.3324/haematol.2015.129858
  4. Artegiani, B., Hendriks, D., Beumer, J., Kok, R., Zheng, X., Joore, I., Chuva de Sousa Lopes, S., van Zon, J., Tans, S. and Clevers, H. (2020) Fast and efficient generation of knock-in human organoids using homology-independent CRISPR-Cas9 precision genome editing. Nat. Cell Biol. 22, 321-331. https://doi.org/10.1038/s41556-020-0472-5
  5. Badon, I. W., Oh, Y., Kim, H. J. and Lee, S. H. (2024) Recent application of CRISPR-Cas12 and OMEGA system for genome editing. Mol. Ther. 32, 32-43. https://doi.org/10.1016/j.ymthe.2023.11.013
  6. Bauer, R. C., Sasaki, M., Cohen, D. M., Cui, J., Smith, M. A., Yenilmez, B. O., Steger, D. J. and Rader, D. J. (2015) Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPalpha. J. Clin. Invest. 125, 3809-3818. https://doi.org/10.1172/JCI77095
  7. Bayarsaikhan, D., Bayarsaikhan, G., Lee, J., Okano, T., Kim, K. and Lee, B. (2025) Development of iPSC-derived FIX-secreting hepatocyte sheet as a novel treatment tool for hemophilia B treatment. Stem Cell Res. Ther. 16, 88.
  8. Bendixen, L., Jensen, T. I. and Bak, R. O. (2023) CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi. Mol. Ther. 31, 1920-1937. https://doi.org/10.1016/j.ymthe.2023.03.024
  9. Berreur, E., Lazzaroni, G., Roth, C., Zihlmann, M., Stirn, M., Matheis, R., Xicluna, R., Breous-Nystrom, E. and Roth, A. B. (2025) iPSChepatocyte organoids as a novel platform to predict AAV gene therapy efficacy. Mol. Ther. Methods Clin. Dev. 33, 101467.
  10. Blassberg, R. (2022) Genome editing of pluripotent stem cells for adoptive and regenerative cell therapies. Gen. Biotechnol. 1, 77-90. https://doi.org/10.1089/genbio.2021.0010
  11. Blaszkiewicz, J. and Duncan, S. A. (2024) Use of stem cell-derived hepatocytes to model liver disease. J. Hepatol. 80, 826-828. https://doi.org/10.1016/j.jhep.2023.11.029
  12. Carlsson, P. O., Hu, X., Scholz, H., Ingvast, S., Lundgren, T., Scholz, T., Eriksson, O., Liss, P., Yu, D., Deuse, T., Korsgren, O. and Schrepfer, S. (2025) Survival of transplanted allogeneic beta cells with no immunosuppression. N. Engl. J. Med. 393, 887-894. https://doi.org/10.1056/NEJMoa2503822
  13. Caron, J., Pene, V., Tolosa, L., Villaret, M., Luce, E., Fourrier, A., Heslan, J. M., Saheb, S., Bruckert, E., Gomez-Lechon, M. J., Nguyen, T. H., Rosenberg, A. R., Weber, A. and Dubart-Kupperschmitt, A. (2019) Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection. Stem Cell Res. Ther. 10, 221. https://doi.org/10.1186/s13287-019-1342-6
  14. Chang, M., Bogacheva, M. S. and Lou, Y. R. (2021) Challenges for the applications of human pluripotent stem cell-derived liver organoids. Front. Cell Dev. Biol. 9, 748576.
  15. Chen, V. L., Du, X., Chen, Y., Kuppa, A., Handelman, S. K., Vohnoutka, R. B., Peyser, P. A., Palmer, N. D., Bielak, L. F., Halligan, B. and Speliotes, E. K. (2021) Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat. Commun. 12, 816.
  16. Chen, Y., Du, X., Kuppa, A., Feitosa, M. F., Bielak, L. F., O'Connell, J. R., Musani, S. K., Guo, X., Kahali, B., Chen, V. L., Smith, A. V., Ryan, K. A., Eirksdottir, G., Allison, M. A., Bowden, D. W., Budoff, M. J., Carr, J. J., Chen, Y. I., Taylor, K. D., Oliveri, A., Correa, A., Crudup, B. F., Kardia, S. L. R., Mosley, T. H., Jr., Norris, J. M., Terry, J. G., Rotter, J. I., Wagenknecht, L. E., Halligan, B. D., Young, K. A., Hokanson, J. E., Washko, G. R., Gudnason, V., Province, M. A., Peyser, P. A., Palmer, N. D. and Speliotes, E. K. (2023) Genomewide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat. Genet. 55, 1640-1650. https://doi.org/10.1038/s41588-023-01497-6
  17. Choi, S. M., Kim, Y., Shim, J. S., Park, J. T., Wang, R. H., Leach, S. D., Liu, J. O., Deng, C., Ye, Z. and Jang, Y. Y. (2013) Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 57, 2458-2468. https://doi.org/10.1002/hep.26237
  18. Collin de l'Hortet, A., Takeishi, K., Guzman-Lepe, J., Morita, K., Achreja, A., Popovic, B., Wang, Y., Handa, K., Mittal, A., Meurs, N., Zhu, Z., Weinberg, F., Salomon, M., Fox, I. J., Deng, C. X., Nagrath, D. and Soto-Gutierrez, A. (2019) Generation of human fatty livers using custom-engineered induced pluripotent stem cells with modifiable SIRT1 metabolism. Cell Metab. 30, 385-401.e9. https://doi.org/10.1016/j.cmet.2019.06.017
  19. DeFrancesco, L. (2025) Precision gene editing medicine makes history, and it's just getting started. Nat. Biotechnol. 43, 1019-1022. https://doi.org/10.1038/s41587-025-02741-6
  20. Deguchi, S., Shintani, T., Harada, K., Okamoto, T., Takemura, A., Hirata, K., Ito, K., Takayama, K. and Mizuguchi, H. (2021) In vitro model for a drug assessment of cytochrome P450 family 3 subfamily a member 4 substrates using human induced pluripotent stem cells and genome editing technology. Hepatol. Commun. 5, 1385-1399. https://doi.org/10.1002/hep4.1729
  21. Deguchi, S., Yamashita, T., Igai, K., Harada, K., Toba, Y., Hirata, K., Takayama, K. and Mizuguchi, H. (2019) Modeling of hepatic drug metabolism and responses in CYP2C19 poor metabolizer using genetically manipulated human iPS cells. Drug Metab. Dispos. 47, 632-638. https://doi.org/10.1124/dmd.119.086322
  22. Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., Liu, H., Cruz, C. R., Savoldo, B., Gee, A. P., Schindler, J., Krance, R. A., Heslop, H. E., Spencer, D. M., Rooney, C. M. and Brenner, M. K. (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683. https://doi.org/10.1056/NEJMoa1106152
  23. Essawi, K., Hakami, W., Naeem Khan, M. B., Martin, R., Zeng, J., Chu, R., Uchida, N., Bonifacino, A. C., Krouse, A. E., Linde, N. S., Donahue, R. E., Blobel, G. A., Gerdemann, U., Kean, L. S., Maitland, S. A., Wolfe, S. A., Metais, J. Y., Gottschalk, S., Bauer, D. E., Tisdale, J. F. and Demirci, S. (2023) Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation. Mol. Ther. Methods Clin. Dev. 29, 483-493. https://doi.org/10.1016/j.omtm.2023.04.004
  24. Friedman, S. L. (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669. https://doi.org/10.1053/j.gastro.2008.03.003
  25. Gaj, T., Gersbach, C. A. and Barbas, C. F., 3rd (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405. https://doi.org/10.1016/j.tibtech.2013.04.004
  26. Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E. and Xiao, J. (2025) Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct. Target. Ther. 10, 33. https://doi.org/10.1038/s41392-024-02072-z
  27. Getachew, H., Metais, T., Daheron, L. and Garita-Hernandez, M. (2025) Advances and optimization strategies in prime editing of human pluripotent stem cells. Trends Biotechnol. doi: 10.1016/j.tibtech.2025.06.017 [Online ahead of print].
  28. Gil, C., Papastavrou, V., Gatti, G., Chung, S., Kiloh, G., Cheung, K., Łukasiak, M., Robinson, C., Panman, L., Kasioulis, I., Nikolaou, N. (2025) iPSC-derived hepatocytes accurately recapitulate population diversity in alpha-1-antitrypsin deficiency and offer a novel in vitro model for large-scale drug efficacy screening studies. bioRxiv doi: 10.1101/2025.01.21.634083 [Preprint].
  29. Gong, J., Tu, W., Liu, J. and Tian, D. (2022) Hepatocytes: a key role in liver inflammation. Front. Immunol. 13, 1083780.
  30. Graffmann, N., Scherer, B. and Adjaye, J. (2022) In vitro differentiation of pluripotent stem cells into hepatocyte like cells - basic principles and current progress. Stem Cell Res. 61, 102763. https://doi.org/10.1016/j.scr.2022.102763
  31. Greig, J. A., Martins, K. M., Breton, C., Lamontagne, R. J., Zhu, Y., He, Z., White, J., Zhu, J. X., Chichester, J. A., Zheng, Q., Zhang, Z., Bell, P., Wang, L. and Wilson, J. M. (2024) Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat. Biotechnol. 42, 1232-1242. https://doi.org/10.1038/s41587-023-01974-7
  32. Guan, Y., Xu, D., Garfin, P. M., Ehmer, U., Hurwitz, M., Enns, G., Michie, S., Wu, M., Zheng, M., Nishimura, T., Sage, J. and Peltz, G. (2017) Human hepatic organoids for the analysis of human genetic diseases. JCI Insight 2, e94954. https://doi.org/10.1172/jci.insight.94954
  33. Hakim, C. H., Kumar, S. R. P., Perez-Lopez, D. O., Wasala, N. B., Zhang, D., Yue, Y., Teixeira, J., Pan, X., Zhang, K., Million, E. D., Nelson, C. E., Metzger, S., Han, J., Louderman, J. A., Schmidt, F., Feng, F., Grimm, D., Smith, B. F., Yao, G., Yang, N. N., Gersbach, C. A., Chen, S. J., Herzog, R. W. and Duan, D. (2021) Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat. Commun. 12, 6769.
  34. Harrison, S. P., Siller, R., Tanaka, Y., Chollet, M. E., de la Morena-Barrio, M. E., Xiang, Y., Patterson, B., Andersen, E., Bravo-Perez, C., Kempf, H., Asrud, K. S., Lunov, O., Dejneka, A., Mowinckel, M. C., Stavik, B., Sandset, P. M., Melum, E., Baumgarten, S., Bonanini, F., Kurek, D., Mathapati, S., Almaas, R., Sharma, K., Wilson, S. R., Skottvoll, F. S., Boger, I. C., Bogen, I. L., Nyman, T. A., Wu, J. J., Bezrouk, A., Cizkova, D., Corral, J., Mokry, J., Zweigerdt, R., Park, I. H. and Sullivan, G. J. (2023) Scalable production of tissue-like vascularized liver organoids from human PSCs. Exp. Mol. Med. 55, 2005-2024. https://doi.org/10.1038/s12276-023-01074-1
  35. Healey, N. (2025) Stem cell therapies advance in Parkinson's disease and beyond. Nat. Med. 31, 2076-2078. https://doi.org/10.1038/d41591-025-00036-6
  36. Hendriks, D., Brouwers, J. F., Hamer, K., Geurts, M. H., Luciana, L., Massalini, S., Lopez-Iglesias, C., Peters, P. J., Rodriguez-Colman, M. J., Chuva de Sousa Lopes, S., Artegiani, B. and Clevers, H. (2023) Engineered human hepatocyte organoids enable CRISPRbased target discovery and drug screening for steatosis. Nat. Biotechnol. 41, 1567-1581. https://doi.org/10.1038/s41587-023-01680-4
  37. Heyne, H. O., Karjalainen, J., Karczewski, K. J., Lemmela, S. M., Zhou, W., FinnGen, Havulinna, A. S., Kurki, M., Rehm, H. L., Palotie, A. and Daly, M. J. (2023) Mono- and biallelic variant effects on disease at biobank scale. Nature 613, 519-525. https://doi.org/10.1038/s41586-022-05420-7
  38. Hidvegi, T., Ewing, M., Hale, P., Dippold, C., Beckett, C., Kemp, C., Maurice, N., Mukherjee, A., Goldbach, C., Watkins, S., Michalopoulos, G. and Perlmutter, D. H. (2010) An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 329, 229-232. https://doi.org/10.1126/science.1190354
  39. Hockemeyer, D. and Jaenisch, R. (2016) Induced pluripotent stem cells meet genome editing. Cell Stem Cell 18, 573-586. https://doi.org/10.1016/j.stem.2016.04.013
  40. Hu, X., White, K., Olroyd, A. G., DeJesus, R., Dominguez, A. A., Dowdle, W. E., Friera, A. M., Young, C., Wells, F., Chu, E. Y., Ito, C. E., Krishnapura, H., Jain, S., Ankala, R., McGill, T. J., Lin, A., Egenberger, K., Gagnon, A., Michael Rukstalis, J., Hogrebe, N. J., Gattis, C., Basco, R., Millman, J. R., Kievit, P., Davis, M. M., Lanier, L. L., Connolly, A. J., Deuse, T. and Schrepfer, S. (2024a) Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat. Biotechnol. 42, 413-423.
  41. Hu, X., White, K., Young, C., Olroyd, A. G., Kievit, P., Connolly, A. J., Deuse, T. and Schrepfer, S. (2024b) Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate. Cell Stem Cell 31, 334-340.e5. https://doi.org/10.1016/j.stem.2024.02.001
  42. Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., Randhawa, R., Kulkarni, T., Yang, Z., McAllister, G., Russ, C., Reece-Hoyes, J., Forrester, W., Hoffman, G. R., Dolmetsch, R. and Kaykas, A. (2018) p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat. Med. 24, 939-946. https://doi.org/10.1038/s41591-018-0050-6
  43. Jin, Y. Y., Zhang, P. and Liu, D. P. (2025) Optimizing homology-directed repair for gene editing: the potential of single-stranded DNA donors. Trends Genet. 41, 788-803. https://doi.org/10.1016/j.tig.2025.04.014
  44. Jing, R., Corbett, J. L., Cai, J., Beeson, G. C., Beeson, C. C., Chan, S. S., Dimmock, D. P., Lazcares, L., Geurts, A. M., Lemasters, J. J. and Duncan, S. A. (2018) A screen using iPSC-derived hepatocytes reveals NAD(+) as a potential treatment for mtDNA depletion syndrome. Cell Rep. 25, 1469-1484.e5. https://doi.org/10.1016/j.celrep.2018.10.036
  45. Ju, R. B., Tian, S. Y., Shang, Y. L., Ma, S. Y., Zhang, M., Liu, J. Y., Sun, K. S., Cui, L. N., Zhou, X. and Han, Y. (2024) Hepatocyte-like cells and liver organoids: the application of iPSCs and their derivants for treating liver diseases. Mater. Adv. 5, 8419-8431. https://doi.org/10.1039/D4MA00373J
  46. Kaserman, J. E., Hurley, K., Dodge, M., Villacorta-Martin, C., Vedaie, M., Jean, J. C., Liberti, D. C., James, M. F., Higgins, M. I., Lee, N. J., Washko, G. R., San Jose Estepar, R., Teckman, J., Kotton, D. N. and Wilson, A. A. (2020) A highly phenotyped open access repository of alpha-1 antitrypsin deficiency pluripotent stem cells. Stem Cell Reports 15, 242-255. https://doi.org/10.1016/j.stemcr.2020.06.006
  47. Kaserman, J. E., Werder, R. B., Wang, F., Matte, T., Higgins, M. I., Dodge, M., Lindstrom-Vautrin, J., Bawa, P., Hinds, A., Bullitt, E., Caballero, I. S., Shi, X., Gerszten, R. E., Brunetti-Pierri, N., Liesa, M., Villacorta-Martin, C., Hollenberg, A. N., Kotton, D. N. and Wilson, A. A. (2022) Human iPSC-hepatocyte modeling of alpha-1 antitrypsin heterozygosity reveals metabolic dysregulation and cellular heterogeneity. Cell Rep. 41, 111775. https://doi.org/10.1016/j.celrep.2022.111775
  48. Kaur, I., Vasudevan, A., Rawal, P., Tripathi, D. M., Ramakrishna, S., Kaur, S. and Sarin, S. K. (2023) Primary hepatocyte isolation and cultures: technical aspects, challenges and advancements. Bioengineering (Basel) 10, 131. https://doi.org/10.3390/bioengineering10020131
  49. Khan, S. and Sallard, E. (2023) Current and prospective applications of CRISPR-Cas12a in pluricellular organisms. Mol. Biotechnol. 65, 196-205. https://doi.org/10.1007/s12033-022-00538-5
  50. Kim, A., Lee, K. G., Kwon, Y., Lee, K. I., Yang, H. M., Habib, O., Kim, J., Kim, S. T., Kim, S. J., Kim, J. S. and Hwang, D. Y. (2021) Off-theshelf, immune-compatible human embryonic stem cells generated via CRISPR-mediated genome editing. Stem Cell Rev. Rep. 17, 1053-1067. https://doi.org/10.1007/s12015-020-10113-7
  51. Kim, D., Kim, S. B., Ryu, J. L., Hong, H., Chang, J. H., Yoo, T. J., Jin, X., Park, H. J., Han, C., Lee, B. H., Choi, J. H., Yoo, H. W., Kim, J. H. and Woo, D. H. (2020a) Human embryonic stem cell-derived Wilson's disease model for screening drug efficacy. Cells 9, 872. https://doi.org/10.3390/cells9040872
  52. Kim, J. W., Im, I., Kim, H., Jeon, J. S., Kang, E. H., Jo, S., Chun, H. S., Yoon, S., Kim, J. H., Kim, S. K. and Park, H. J. (2020b) Livecell screening platform using human-induced pluripotent stem cells expressing fluorescence-tagged cytochrome P450 1A1. FASEB J. 34, 9141-9155. https://doi.org/10.1096/fsb2.v34.7
  53. Kim, M., Song, E. S., Chen, J. C., Chatterjee, S., Sun, Y., Lee, S. M., Wu, S., Patel, P., Tian, Z., Kantor, A., Wustman, B. A., Lockhart, D. J. and Siegwart, D. J. (2025a) Dual SORT LNPs for multi-organ base editing. Nat. Biotechnol. doi: 10.1038/s41587-025-02675-z[Online ahead of print].
  54. Kim, Y., Kang, M., Mamo, M. G., Adisasmita, M., Huch, M. and Choi, D. (2025b) Liver organoids: current advances and future applications for hepatology. Clin. Mol. Hepatol. 31, S327-S348. https://doi.org/10.3350/cmh.2024.1040
  55. Kim, Y. H., Kim, N., Okafor, I., Choi, S., Min, S., Lee, J., Bae, S. M., Choi, K., Choi, J., Harihar, V., Kim, Y., Kim, J. S., Kleinstiver, B. P., Lee, J. K., Ha, T. and Kim, H. H. (2023) Sniper2L is a high-fidelity Cas9 variant with high activity. Nat. Chem. Biol. 19, 972-980. https://doi.org/10.1038/s41589-023-01279-5
  56. King, E. A., Davis, J. W. and Degner, J. F. (2019) Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489. https://doi.org/10.1371/journal.pgen.1008489
  57. Kitano, Y., Nishimura, S., Kato, T. M., Ueda, A., Takigawa, K., Umekage, M., Nomura, M., Kawakami, A., Ogawa, H., Xu, H., Hotta, A., Takasu, N. and Tsukahara, M. (2022) Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application. Mol. Ther. Methods Clin. Dev. 26, 15-25. https://doi.org/10.1016/j.omtm.2022.05.010
  58. Lee, P. C., Truong, B., Vega-Crespo, A., Gilmore, W. B., Hermann, K., Angarita, S. A., Tang, J. K., Chang, K. M., Wininger, A. E., Lam, A. K., Schoenberg, B. E., Cederbaum, S. D., Pyle, A. D., Byrne, J. A. and Lipshutz, G. S. (2016) Restoring ureagenesis in hepatocytes by CRISPR/Cas9-mediated genomic addition to arginase-deficient induced pluripotent stem cells. Mol. Ther. Nucleic Acids 5, e394. https://doi.org/10.1038/mtna.2016.98
  59. Li, S., Li, M., Liu, X., Yang, Y., Wei, Y., Chen, Y., Qiu, Y., Zhou, T., Feng, Z., Ma, D., Fang, J., Ying, H., Wang, H., Musunuru, K., Shao, Z., Zhao, Y. and Ding, Q. (2018) Genetic and chemical screenings identify HDAC3 as a key regulator in hepatic differentiation of human pluripotent stem cells. Stem Cell Reports 11, 22-31. https://doi.org/10.1016/j.stemcr.2018.05.001
  60. Li, Y., Nie, Y. and Taniguchi, H. (2025) Protocol for generating liver organoids containing Kupffer cells using human iPSCs. STAR Protoc. 6, 104138. https://doi.org/10.1016/j.xpro.2025.104138
  61. Liao, H., Wu, J., VanDusen, N. J., Li, Y. and Zheng, Y. (2024) CRISPRCas9-mediated homology-directed repair for precise gene editing. Mol. Ther. Nucleic Acids 35, 102344. https://doi.org/10.1016/j.omtn.2024.102344
  62. Lim, D., Sreekanth, V., Cox, K. J., Law, B. K., Wagner, B. K., Karp, J. M. and Choudhary, A. (2020) Engineering designer beta cells with a CRISPR-Cas9 conjugation platform. Nat. Commun. 11, 4043.
  63. Lim, D., Zhou, Q., Cox, K. J., Law, B. K., Lee, M., Kokkonda, P., Sreekanth, V., Pergu, R., Chaudhary, S. K., Gangopadhyay, S. A., Maji, B., Lai, S., Amako, Y., Thompson, D. B., Subramanian, H. K. K., Mesleh, M. F., Dancik, V., Clemons, P. A., Wagner, B. K., Woo, C. M., Church, G. M. and Choudhary, A. (2022) A general approach to identify cell-permeable and synthetic anti-CRISPR small molecules. Nat. Cell Biol. 24, 1766-1775. https://doi.org/10.1038/s41556-022-01005-8
  64. Liu, S., Cheng, C., Zhu, L., Zhao, T., Wang, Z., Yi, X., Yan, F., Wang, X., Li, C., Cui, T. and Yang, B. (2024a) Liver organoids: updates on generation strategies and biomedical applications. Stem Cell Res. Ther. 15, 244. https://doi.org/10.1186/s13287-024-03865-3
  65. Liu, S. S., Shim, S., Kudo, Y., Stabler, C. L., O'Cearbhaill, E. D., Karp, J. M. and Yang, K. (2024b) Encapsulated islet transplantation. Nat. Rev. Bioeng. 3, 83-102. https://doi.org/10.1038/s44222-024-00238-6
  66. Luce, E., Messina, A., Duclos-Vallee, J. C. and Dubart-Kupperschmitt, A. (2021) Advanced Techniques and awaited clinical applications for human pluripotent stem cell differentiation into hepatocytes. Hepatology 74, 1101-1116. https://doi.org/10.1002/hep.31705
  67. Łukasiak, M., Gatti, G., Chung, S., Kiloh, G., Robinson, C., Kasioulis, I., Gil, C., Panman, L. and Nikolaou, N. (2024) Development of optimised human iPSC-derived hepatocytes with improved liver 1 function for in vitro metabolic disease modelling and toxicity studies. bioRixv doi: 10.1101/2024.11.18.624145 [Preprint].
  68. Luo, Q., Wang, N., Que, H., Mai, E., Hu, Y., Tan, R., Gu, J. and Gong, P. (2023) Pluripotent stem cell-derived hepatocyte-like cells: induction methods and applications. Int. J. Mol. Sci. 24. 11592.
  69. Lyu, C., Shen, J., Wang, R., Gu, H., Zhang, J., Xue, F., Liu, X., Liu, W., Fu, R., Zhang, L., Li, H., Zhang, X., Cheng, T., Yang, R. and Zhang, L. (2018) Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system. Stem Cell Res. Ther. 9, 92. https://doi.org/10.1186/s13287-018-0839-8
  70. Martin, R. M., Fowler, J. L., Cromer, M. K., Lesch, B. J., Ponce, E., Uchida, N., Nishimura, T., Porteus, M. H. and Loh, K. M. (2020) Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat. Commun. 11, 2713.
  71. Masek, J. and Andersson, E. R. (2024) Jagged-mediated development and disease: mechanistic insights and therapeutic implications for Alagille syndrome. Curr. Opin. Cell Biol. 86, 102302.
  72. Miki, T., Vazquez, L., Yanuaria, L., Lopez, O., Garcia, I. M., Ohashi, K. and Rodriguez, N. S. (2019) Induced pluripotent stem cell derivation and ex vivo gene correction using a mucopolysaccharidosis type 1 disease mouse model. Stem Cells Int. 2019, 6978303. https://doi.org/10.1155/2019/6978303
  73. Minikel, E. V. and Nelson, M. R. (2025) Human genetic evidence enriched for side effects of approved drugs. PLoS Genet. 21, e1011638. https://doi.org/10.1371/journal.pgen.1011638
  74. Minikel, E. V., Painter, J. L., Dong, C. C. and Nelson, M. R. (2024) Refining the impact of genetic evidence on clinical success. Nature 629, 624-629. https://doi.org/10.1038/s41586-024-07316-0
  75. Movahed, A. Y., Bagheri, R., Savatier, P., Saric, T. and Moradi, S. (2025) Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: an important step toward ensuring safe cell therapy. Stem Cell Reports 20, 102543. https://doi.org/10.1016/j.stemcr.2025.102543
  76. Musunuru, K., Grandinette, S. A., Wang, X., Hudson, T. R., Briseno, K., Berry, A. M., Hacker, J. L., Hsu, A., Silverstein, R. A., Hille, L. T., Ogul, A. N., Robinson-Garvin, N. A., Small, J. C., McCague, S., Burke, S. M., Wright, C. M., Bick, S., Indurthi, V., Sharma, S., Jepperson, M., Vakulskas, C. A., Collingwood, M., Keogh, K., Jacobi, A., Sturgeon, M., Brommel, C., Schmaljohn, E., Kurgan, G., Osborne, T., Zhang, H., Kinney, K., Rettig, G., Barbosa, C. J., Semple, S. C., Tam, Y. K., Lutz, C., George, L. A., Kleinstiver, B. P., Liu, D. R., Ng, K., Kassim, S. H., Giannikopoulos, P., Alameh, M. G., Urnov, F. D. and Ahrens-Nicklas, R. C. (2025) Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235-2243. https://doi.org/10.1056/NEJMoa2504747
  77. Nagarajan, S. R., Paul-Heng, M., Krycer, J. R., Fazakerley, D. J., Sharland, A. F. and Hoy, A. J. (2019) Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: a comprehensive resource for in vitro studies of hepatic metabolism. Am. J. Physiol. Endocrinol. Metab. 316, E578-E589. https://doi.org/10.1152/ajpendo.00365.2018
  78. Naito, C., Kosar, K., Kishimoto, E., Pena, L., Huang, Y., Hao, K., Bernieh, A., Kasten, J., Villa, C., Kishnani, P., Deeksha, B., Gu, M. and Asai, A. (2024) Induced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen storage disease IV. Mol. Genet. Metab. Rep. 39, 101069. https://doi.org/10.1016/j.ymgmr.2024.101069
  79. Omer, L., Hudson, E. A., Zheng, S., Hoying, J. B., Shan, Y. and Boyd, N. L. (2017) CRISPR Correction of a homozygous low-density lipo-protein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells. Hepatol. Commun. 1, 886-898. https://doi.org/10.1002/hep4.1110
  80. Ortuno-Costela, M. C., Pinzani, M. and Vallier, L. (2025) Cell therapy for liver disorders: past, present and future. Nat. Rev. Gastroenterol. Hepatol. 22, 329-342. https://doi.org/10.1038/s41575-025-01050-2
  81. Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., McCauley, H. A., Zhang, R. R., Lewis, K., Hakozaki, S., Ferguson, A., Saiki, N., Yoneyama, Y., Takeuchi, I., Mabuchi, Y., Akazawa, C., Yoshikawa, H. Y., Wells, J. M. and Takebe, T. (2019) Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab. 30, 374-384.e6. https://doi.org/10.1016/j.cmet.2019.05.007
  82. Pandey, S., Gao, X. D., Krasnow, N. A., McElroy, A., Tao, Y. A., Duby, J. E., Steinbeck, B. J., McCreary, J., Pierce, S. E., Tolar, J., Meissner, T. B., Chaikof, E. L., Osborn, M. J. and Liu, D. R. (2025) Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat. Biomed. Eng. 9, 22-39.
  83. Park, G., Rim, Y. A., Sohn, Y., Nam, Y. and Ju, J. H. (2024) Replacing animal testing with stem cell-organoids : advantages and limitations. Stem Cell Rev. Rep. 20, 1375-1386. https://doi.org/10.1007/s12015-024-10723-5
  84. Pashos, E. E., Park, Y., Wang, X., Raghavan, A., Yang, W., Abbey, D., Peters, D. T., Arbelaez, J., Hernandez, M., Kuperwasser, N., Li, W., Lian, Z., Liu, Y., Lv, W., Lytle-Gabbin, S. L., Marchadier, D. H., Rogov, P., Shi, J., Slovik, K. J., Stylianou, I. M., Wang, L., Yan, R., Zhang, X., Kathiresan, S., Duncan, S. A., Mikkelsen, T. S., Morrisey, E. E., Rader, D. J., Brown, C. D. and Musunuru, K. (2017) Large, diverse population cohorts of hiPSCs and derived hepatocyte-like cells reveal functional genetic variation at blood lipid-associated loci. Cell Stem Cell 20, 558-570.e10.
  85. Philippidis, A. (2024) CASGEVY makes history as FDA approves first CRISPR/Cas9 genome edited therapy. Hum. Gene Ther. 35, 1-4. https://doi.org/10.1089/hum.2023.29263.bfs
  86. Ran, F. A., Hsu, P. D., Lin, C. Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y. and Zhang, F. (2013) Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389. https://doi.org/10.1016/j.cell.2013.08.021
  87. Reuven, N. and Shaul, Y. (2022) Selecting for CRISPR-Edited KnockIn Cells. Int. J. Mol. Sci. 23, 11919.
  88. Reza, H. A., Okabe, R. and Takebe, T. (2021) Organoid transplant approaches for the liver. Transpl. Int. 34, 2031-2045. https://doi.org/10.1111/tri.v34.11
  89. Reza, H. A., Santangelo, C., Iwasawa, K., Reza, A. A., Sekiya, S., Glaser, K., Bondoc, A., Merola, J. and Takebe, T. (2025) Multi-zonal liver organoids from human pluripotent stem cells. Nature 641, 1258-1267. https://doi.org/10.1038/s41586-025-08850-1
  90. Rossiaud, L., Fragner, P., Barbon, E., Gardin, A., Benabides, M., Pellier, E., Cosette, J., El Kassar, L., Giraud-Triboult, K., Nissan, X., Ronzitti, G. and Hoch, L. (2023) Pathological modeling of glycogen storage disease type III with CRISPR/Cas9 edited human pluripotent stem cells. Front. Cell Dev. Biol. 11, 1163427.
  91. Samadi, A., Moammeri, A., Pourmadadi, M., Abbasi, P., Hosseinpour, Z., Farokh, A., Shamsabadipour, A., Heydari, M. and Mohammadi, M. R. (2023) Cell encapsulation and 3D bioprinting for therapeutic cell transplantation. ACS Biomater. Sci. Eng. 9, 1862-1890. https://doi.org/10.1021/acsbiomaterials.2c01183
  92. Sanchez, P., Farkhondeh, A., Pavlinov, I., Baumgaertel, K., Rodems, S. and Zheng, W. (2021) Therapeutics development for alagille syndrome. Front. Pharmacol. 12, 704586.
  93. Schene, I. F., Joore, I. P., Oka, R., Mokry, M., van Vugt, A. H. M., van Boxtel, R., van der Doef, H. P. J., van der Laan, L. J. W., Verstegen, M. M. A., van Hasselt, P. M., Nieuwenhuis, E. E. S. and Fuchs, S. A. (2020) Prime editing for functional repair in patient-derived disease models. Nat. Commun. 11, 5352.
  94. Schulze, R. J., Schott, M. B., Casey, C. A., Tuma, P. L. and McNiven, M. A. (2019) The cell biology of the hepatocyte: a membrane trafficking machine. J. Cell Biol. 218, 2096-2112. https://doi.org/10.1083/jcb.201903090
  95. Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G. and Miranda, J. P. (2021) A critical perspective on 3D liver models for drug metabolism and toxicology studies. Front. Cell Dev. Biol. 9, 626805.
  96. Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., Paschon, D. E., Miller, J. C., Davidson, R. J., Shivak, D., Zhou, S., Rieders, J., Gregory, P. D., Holmes, M. C., Rebar, E. J. and High, K. A. (2015) In vivo genome editing of the albumin locus as a platform for protein replacement therapy. Blood 126, 1777-1784. https://doi.org/10.1182/blood-2014-12-615492
  97. Shi, P. and Wu, X. (2024) Programmable RNA targeting with CRISPRCas13. RNA Biol. 21, 1-9. https://doi.org/10.1080/15476286.2024.2351657
  98. Simoni, C., Barbon, E., Muro, A. F. and Cantore, A. (2024) In vivo liver targeted genome editing as therapeutic approach: progresses and challenges. Front. Genome Ed. 6, 1458037. https://doi.org/10.3389/fgeed.2024.1458037
  99. Sin, Y. Y., Ballantyne, L. L., Richmond, C. R. and Funk, C. D. (2018) Transplantation of gene-edited hepatocyte-like cells modestly improves survival of arginase-1-deficient mice. Mol. Ther. Nucleic Acids 10, 122-130.
  100. Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X. and Zhang, F. (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88. https://doi.org/10.1126/science.aad5227
  101. Smith, I., Greenside, P. G., Natoli, T., Lahr, D. L., Wadden, D., Tirosh, I., Narayan, R., Root, D. E., Golub, T. R., Subramanian, A. and Doench, J. G. (2017) Evaluation of RNAi and CRISPR technologies by large-scale gene expression profiling in the Connectivity Map. PLoS Biol. 15, e2003213. https://doi.org/10.1371/journal.pbio.2003213
  102. Stojic, L., Lun, A. T. L., Mangei, J., Mascalchi, P., Quarantotti, V., Barr, A. R., Bakal, C., Marioni, J. C., Gergely, F. and Odom, D. T. (2018) Specificity of RNAi, LNA and CRISPRi as loss-of-function methods in transcriptional analysis. Nucleic Acids Res. 46, 5950-5966. https://doi.org/10.1093/nar/gky437
  103. Sung, K., Jung, Y., Kim, N., Kim, Y. W., Kim, H. H., Kim, S. K. and Bae, S. (2025) A rational engineering strategy for structural dynamics modulation enables target specificity enhancement of the Cas9 nuclease. Nucleic Acids Res. 53, gkaf535. https://doi.org/10.1093/nar/gkaf535
  104. Tadokoro, T., Murata, S., Kato, M., Ueno, Y., Tsuchida, T., Okumura, A., Kuse, Y., Konno, T., Uchida, Y., Yamakawa, Y., Zushi, M., Yajima, M., Kobayashi, T., Hasegawa, S., Kawakatsu-Hatada, Y., Hayashi, Y., Osakabe, S., Maeda, T., Kimura, K., Mori, A., Tanaka, M., Kamishibahara, Y., Matsuo, M., Nie, Y. Z., Okamoto, S., Oba, T., Tanimizu, N. and Taniguchi, H. (2024) Human iPSC-liver organoid transplantation reduces fibrosis through immunomodulation. Sci. Transl. Med. 16, eadg0338. https://doi.org/10.1126/scitranslmed.adg0338
  105. Takayama, K., Hagihara, Y., Toba, Y., Sekiguchi, K., Sakurai, F. and Mizuguchi, H. (2018) Enrichment of high-functioning human iPS cell-derived hepatocyte-like cells for pharmaceutical research. Biomaterials 161, 24-32. https://doi.org/10.1016/j.biomaterials.2018.01.019
  106. Tilson, S. G., Morell, C. M., Lenaerts, A. S., Park, S. B., Hu, Z., Jenkins, B., Koulman, A., Liang, T. J. and Vallier, L. (2021) Modeling PNPLA3-associated NAFLD using human-induced pluripotent stem cells. Hepatology 74, 2998-3017. https://doi.org/10.1002/hep.32063
  107. Uchida, T., Park, S. B., Inuzuka, T., Zhang, M., Allen, J. N., Chayama, K. and Liang, T. J. (2021) Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection. Mol. Ther. Methods Clin. Dev. 23, 597-605. https://doi.org/10.1016/j.omtm.2021.11.002
  108. Velazquez, J. J., LeGraw, R., Moghadam, F., Tan, Y., Kilbourne, J., Maggiore, J. C., Hislop, J., Liu, S., Cats, D., Chuva de Sousa Lopes, S. M., Plaisier, C., Cahan, P., Kiani, S. and Ebrahimkhani, M. R. (2021) Gene regulatory network analysis and engineering directs development and vascularization of multilineage human liver organoids. Cell Syst. 12, 41-55.e11. https://doi.org/10.1016/j.cels.2020.11.002
  109. Viscomi, C. and Zeviani, M. (2017) MtDNA-maintenance defects: syndromes and genes. J. Inherit. Metab. Dis. 40, 587-599. https://doi.org/10.1007/s10545-017-0027-5
  110. Walsh, C. and Jin, S. (2024) Induced pluripotent stem cells and CRISPR-Cas9 innovations for treating alpha-1 antitrypsin deficiency and glycogen storage diseases. Cells 13, 1052. https://doi.org/10.3390/cells13121052
  111. Wang, H., Wen, L., Jiang, F., Ren, P., Yang, Y., Song, S., Yang, Z. and Wang, Y. (2024) A comprehensive review of advances in hepatocyte microencapsulation: selecting materials and preserving cell viability. Front. Immunol. 15, 1385022. https://doi.org/10.3389/fimmu.2024.1385022
  112. Wang, L., Breton, C., Warzecha, C. C., Bell, P., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., Jantz, D. and Wilson, J. M. (2021) Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol. Ther. 29, 2019-2029. https://doi.org/10.1016/j.ymthe.2021.02.020
  113. Wei, R., Yang, J., Cheng, C. W., Ho, W. I., Li, N., Hu, Y., Hong, X., Fu, J., Yang, B., Liu, Y., Jiang, L., Lai, W. H., Au, K. W., Tsang, W. L., Tse, Y. L., Ng, K. M., Esteban, M. A. and Tse, H. F. (2022) CRISPRtargeted genome editing of human induced pluripotent stem cellderived hepatocytes for the treatment of Wilson's disease. JHEP Rep. 4, 100389. https://doi.org/10.1016/j.jhepr.2021.100389
  114. Weng, Y., Han, S., Sekyi, M. T., Su, T., Mattis, A. N. and Chang, T. T. (2023) Self-assembled matrigel-free iPSC-derived liver organoids demonstrate wide-ranging highly differentiated liver functions. Stem Cells 41, 126-139. https://doi.org/10.1093/stmcls/sxac090
  115. Werder, R. B., Kaserman, J. E., Packer, M. S., Lindstrom-Vautrin, J., Villacorta-Martin, C., Young, L. E., Aratyn-Schaus, Y., Gregoire, F. and Wilson, A. A. (2021) Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes. Mol. Ther. 29, 3219-3229. https://doi.org/10.1016/j.ymthe.2021.06.021
  116. Wiebking, V., Patterson, J. O., Martin, R., Chanda, M. K., Lee, C. M., Srifa, W., Bao, G. and Porteus, M. H. (2020) Metabolic engineering generates a transgene-free safety switch for cell therapy. Nat. Biotechnol. 38, 1441-1450. https://doi.org/10.1038/s41587-020-0580-6
  117. Wu, H., Wang, J., Liu, S., Wang, Y., Tang, X., Xie, J., Wang, N., Shan, H., Chen, S., Zhang, X., Zeng, W., Chen, C., Fu, Y., Lai, L. and Duan, Y. (2025a) Large-scale production of expandable hepatoblast organoids and polarised hepatocyte organoids from hESCs under 3D static and dynamic suspension conditions. Cell Prolif. 58, e70001. https://doi.org/10.1111/cpr.v58.7
  118. Wu, L., Li, Z., Wang, K., Groleau, R. R., Rong, X., Liu, X., Liu, C., Lewis, S. E., Zhu, B. and James, T. D. (2025b) Advances in organic small molecule-based fluorescent probes for precision detection of liver diseases: a perspective on emerging trends and challenges. J. Am. Chem. Soc. 147, 9001-9018. https://doi.org/10.1021/jacs.4c17092
  119. Wu, W. Y., Adiego-Perez, B. and van der Oost, J. (2024) Biology and applications of CRISPR-Cas12 and transposon-associated homologs. Nat. Biotechnol. 42, 1807-1821. https://doi.org/10.1038/s41587-024-02485-9
  120. Xu, H., Wang, B., Ono, M., Kagita, A., Fujii, K., Sasakawa, N., Ueda, T., Gee, P., Nishikawa, M., Nomura, M., Kitaoka, F., Takahashi, T., Okita, K., Yoshida, Y., Kaneko, S. and Hotta, A. (2019) Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566-578.e7. https://doi.org/10.1016/j.stem.2019.02.005
  121. Xu, W., Zhang, S., Qin, H. and Yao, K. (2024) From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine. J. Transl. Med. 22, 1133.
  122. Yuan, Y., Cotton, K., Samarasekera, D. and Khetani, S. R. (2023) Engineered platforms for maturing pluripotent stem cell-derived liver cells for disease modeling. Cell. Mol. Gastroenterol. Hepatol. 15, 1147-1160. https://doi.org/10.1016/j.jcmgh.2023.01.013
  123. Zabulica, M., Jakobsson, T., Ravaioli, F., Vosough, M., Gramignoli, R., Ellis, E., Rooyackers, O. and Strom, S. C. (2021) Gene editing correction of a urea cycle defect in organoid stem cell derived hepatocyte-like cells. Int. J. Mol. Sci. 22, 1217.
  124. Zhang, K., Wu, N., Cen, J., Li, J., Wang, Z., Xia, Q. and Hui, L. (2023) Ex vivo factor VIII-modified proliferating human hepatocytes therapy for haemophilia A. Cell Prolif. 56, e13467. https://doi.org/10.1111/cpr.v56.5
  125. Zhang, L., Wang, X., Yang, X., Chi, Y., Chu, Y., Zhang, Y., Gong, Y., Wang, F., Zhao, Q. and Zhao, D. (2024) Genome engineering of primary and pluripotent stem cell-derived hepatocytes for modeling liver tumor formation. Biology (Basel) 13, 684. https://doi.org/10.3390/biology13090684
  126. Zhao, J., Zhi, Y., Ren, H., Wang, J. and Zhao, Y. (2025) Emerging biotechnologies for engineering liver organoids. Bioact. Mater. 45, 1-18. https://doi.org/10.1016/j.bioactmat.2024.11.002
  127. Zhou, L., Huang, J., Li, C., Gu, Q., Li, G., Li, Z. A., Xu, J., Zhou, J. and Tuan, R. S. (2025) Organoids and organs-on-chips: recent advances, applications in drug development, and regulatory challenges. Med 6, 100667. https://doi.org/10.1016/j.medj.2025.100667
  128. Zhou, L. and Yao, S. (2023) Recent advances in therapeutic CRISPRCas9 genome editing: mechanisms and applications. Mol. Biomed. 4, 10.